Dementia Prescribing Guide (1 MB) - Guidelines
Version 2 Uploaded May 2022
Date added: 31st Jul 2017
Drug Name | Classification | Clinical Indication | Comments |
---|---|---|---|
3,4 DIAMINOPYRIDINE (NEW) | Red | Lambert Eaton Myasthenic Syndrome |
Unlicensed |
ABATACEPT (NEW) | Red | Refractory idiopathic inflammatory myopathies (adults and children aged 2 years and over) | |
ACITRETIN (UPDATED) | Red | For psoriasis, Icthyosis, palmoplantar pustulosis and Dariers disease in males and postmenopausal women. |
Reviewed by TAS 22nd June 2021 |
ALEMTUZUMAB | Red |
Relapsing, remitting multiple sclerosis |
In line with NICE TA 312 |
ANAKINRA (Kineret®) (NEW) | Red | Haemophagocytic Lymphohistiocytisis | |
BALOXAVIR MARBOXIL (Xofluza®) (NEW) | Grey | Treatment and post exposure prophylaxis of influenza | |
BELIMUMAB (NEW) | Red | For treating active autoantibody positive systemic lupus erythematosus |
In line with NICE TA752. Implementation date 15th March 2022 |
BEMIPARIN (Zibor ®) (NEW) | Grey | Prevention of thromboembolic disease. Prevention of clotting. | |
BEVACIZUMAB (NEW) | Red | Treatment of angiodysplasia in the background of von Willebrand's disease second line to thalidomide use. | |
BLEPHACLEAN WIPES (NEW) | Do not prescribe | Blepharitis | |
BUPRENORPHINE IMPLANT (Sixmo ® (implant)) (NEW) | Grey | Substitution treatment for opioid dependence in clinically stable patients. | |
BUPRENORPHINE PROLONGED RELEASE INJECTION (Buvidal®) | Red | Substance misuse |
Used by Turning Point . If a patient is admitted to hospital contact turning point for advice about alternatives: 0116 3732117 – Direct dial to prescribing team 0116 3732108 – Direct Dial to Clinical Admin 0330 303 6000 – Main Switchboard |
CABOTEGRAVIR WITH RILPIVIRINE (NEW) | Red | For treating HIV-1 |
In line with NICE TA757. Implementation date 5th April. |
CENOBAMATE (NEW) | Red | Focal onset seizures in epilepsy | |
CHLORAL HYDRATE/CLORAL BETAINE (NEW) | Red | Insomnia in children and adolescents |
Traffic light change following MHRA restrictions. Should not be stopped suddenly, so there will need to be some continuation in primary care in the short term. |
CHLORMETHINE GEL (Ledaga®) (NEW) | Red | Mycosis fungoides-type T cell lymphomas |
In line with NICE TA720 |
COLISTIN (NEW) | Red | Nebulised for Cystic fibrosis | |
COLISTIN (Colomycin® and Promixin ®) | Orange | Nebulised for cystic fibrosis |
Historic patients only. Must be prescribed by brand as the brands are not interchangeable. |
CRIZANLIZUMAB (NEW) | Red | Preventing sickle cell crises in sickle cell disease |
In line with NICE TA743 |
DANTROLENE LIQUID (NEW) | Red | severe chronic spasticity |
Please note this traffic light is for the liquid preparation. |
DAPAGLIFLOZIN (NEW) | Do not prescribe | Type 1 diabetes |
New patients |
DAPAGLIFLOZIN (UPDATED) | Yellow | With insulin for treating Type 1 diabetes |
Now unlicensed due to commercial reasons
|
DEOXYCHOLIC ACID (Belkyra ®) (NEW) | Grey | Moderate to severe convexity or fullness associated with submental fat in adults when the presence of submental fat has an important psychological impact for the patient | |
DEXAMFETAMINE (NEW) | Orange | Excessive sleepiness caused by narcolepsy | |
DIROXIMEL FUMERATE (Vumerity®) (NEW) | Grey | Relapsing-remitting multiple sclerosis | |
DUPILUMAB (NEW) | Red | Severe asthma with type 2 inflammation |
In line with NICE TA751. Implementation date 8th March 2022 |
EMPAGLIFLOZIN (NEW) | Yellow | Chronic heart failure with reduced ejection fraction. |
In line with NICE TA773 |
ERAVACYCLINE (Xerava®) (NEW) | Grey | Complicated intra-abdominal infections in adults | |
ESKETAMINE HYDROCHLORIDE NASAL SPRAY (Spravato®) (UPDATED) | Red | In combination with a SSRI or SNRI for adults with treatment-resistant Major Depressive Disorder |
Administration in specialist clinic only |
ESTRADIOL HEMIHYDRATE/NORETHISTERONE ACETATE/RELUGOLIX (Ryeqo ®) (NEW) | Grey | Treatment of moderate to severe symptoms of uterine fibroids in adult women of reproductive age. | |
FENFLURAMINE HYDROCHLORIDE (Fintepla ®) (NEW) | Grey | Treatment of seizures associated with Dravet syndrome as an add-on therapy to other anti-epileptic medicines. | |
FOSTEMSAVIR (Rukobia ®) (NEW) | Red | HIV Infections | |
FREMANEZUMAB (Ajovy®) (UPDATED) | Red | Prevention of migraine |
In line with NICE TA764 |
GALANTAMINE Gazylan XL ® (UPDATED) | Yellow | Alzheimer's disease | |
GALANTAMINE LIQUID (UPDATED) | Red | Alzheimer's disease |
Leicestershire Partnership Trust consultants only |
GLYCEROL PHENYLBUTYRATE (Ravicti®) (UPDATED) | Red | Chronic management of patients with urea cycle disorders (UCDs) | |
Herpes ZOSTER vaccine | Do not prescribe | All indications outside of the green book. Zostavax is a live vaccine, therefore NOT suitable for immunocompromised patients. Do not prescribe on FP10 (black through this route). |
Available centrally from 1st Sept 2013 for those aged 70 and 79 years |
HYDROCORTISONE (Alkindi®)(Granules in capsules for opening) (UPDATED) | Yellow | Adrenal insufficiency in paediatrics | |
ICOSAPENT ETHYL (Vazkepa ®) (NEW) | Grey | Reduce the risk of cardiovascular events. | |
INCLISIRAN (Leqvio®) (NEW) | Green | Treating primary hypercholesterolaemia or mixed dyslipidaemia. SECONDARY PREVENTION ONLY as per NICE TA733 |
For prescribers who feel competent to use this medication. In line with NICE TA733. The AAC Lipid management pathway gives further guidance on place in therapy and the AHSN have some inclisiran FAQS. Please see the Cardiovascular Guideline page |
INHALED DRY POWDER BUDESONIDE (UPDATED) | Do not prescribe | Covid 19 treatment |
No longer recommended for Covid treatment outside of a trial in line with CAS 103185
|
LIRAGLUTIDE (Saxenda®) (NEW) | Red | Obesity in children aged over 12 years | |
LIRAGLUTIDE (Victoza®) (NEW) | Yellow | Type 2 diabetes mellitus in children 10 years and over | |
LURASIDONE (UPDATED) | Orange | Schizophrenia aged 13-17 years | |
MACROGOL 3350 (TransiSoft®) (NEW) | Grey | Chronic constipation, use usually limited to 2 weeks |
Not to mixed up with other macrogol products such as Macrogol oral powder compound e.g. Laxido or Movicol |
MELATONIN M/R 1mg and 5mg tablets (Slenyto®) (UPDATED) | Yellow | Insomnia for children aged 2-18 years with Autism Spectrum Disorder and or Smith-Magenis syndrome | |
METHYLPHENIDATE (NEW) | Orange | Excessive sleepiness caused by narcolepsy | |
METRELEPTIN (Myalepta ®) (NEW) | Grey | Replacement therapy to treat the complications of leptin deficiency in lipodystrophy patients. | |
MEXILETINE (Namuscla®) | Do not prescribe | Symptomatic treatment of myotonia in adult patients with non-dystrophic myotonic disorders |
In line with NICE TA748 this product should be used by specialist centres only. At the time of classification LLR is not a site of a specialist centre. |
NEFOPAM (NEW) | Green | Pain |
Non-formulary so use by exception only |
NINTEDANIB (NEW) | Red | Fibrosing interstitial lung diseases |
In line with NICE TA747. Implementation date 17th February 2022. |
OCTREOTIDE (UPDATED) | Red | Hight output stoma | |
ODEVIXIBAT SESQUIHYDRATE (Bylvay®) (NEW) | Grey | Treatment of progressive familial intrahepatic cholestasis in patients aged 6 months or older. | |
PALFORZIA (NEW) | Red | Treating peanut allergy in children and young people. |
In line with NICE TA769 Implementation date 2nd May 2022 |
PEGCETACOPLAN (NEW) | Do not prescribe | Paroxysmal nocturnal haemoglobinuria (PMH) |
Recommended by NICE TA788 but all prescribing is via the national PMH centre |
PITOLISANT (NEW) | Do not prescribe | Excessive daytime sleepiness caused by obstructive sleep apnoea |
Not recommended by NICE TA776 |
PONESIMOD (Ponvory®) (UPDATED) | Red | Relapsing forms of multiple sclerosis with active disease. |
In line with NICE TA767 Implementation date 2nd May 2022 |
RISDIPLAM (NEW) | Do not prescribe | Spinal Muscular Atrophy |
Approved centres only. LLR is currently not an approved centre. |
RITUXIMAB (NEW) | Do not prescribe | IgM paraproteinaemic demyelinating peripheral neuropathy in adults |
Approved centres only. LLR is currently not an approved centre. |
RIVAROXABAN (Xarelto®) (NEW) | Yellow | Treatment of VTE in paediatric patients | |
ROXADUSTAT (Evrenzo ®) (NEW) | Grey | Symptomatic anaemia associated with chronic kidney disease (CKD) in adults | |
RUPATADINE (NEW) | Red | Urticaria in paediatrics | |
SALMETEROL / FLUTICASONE INHALATION POWDER (Seffalair Spiromax ®) (NEW) | Grey | Asthma | |
SAPROPTERIN (NEW) | Red | Hyperphenylalaninaemia in phenylketonuria |
In line with NICE TA729 |
SECUKINUMAB (Cosentyx®) (NEW) | Red | Treating moderate to severe plaque psoriasis in children and young people |
In line with NICE TA734
|
SOLRIAMFETOL (Sunosi ®) (UPDATED) | Do not prescribe | Sleepiness in patients treated with CPAP for obstructive sleep apnoea |
Not recommended by NICE for this indication |
TIPRANAVIR (UPDATED) | Do not prescribe | HIV infection |
Discontinued |
TOFACITINIB (NEW) | Red | Juvenile idiopathic arthritis |
In line with NICE TA735 Implementation date 20th January 2022 |
TOLVAPTAN (Samsca®) (UPDATED) | Red | Hyponatraemia secondary to SIADH in patients requiring cancer chemotherapy | |
UPADACITINIB (Rinvoq®) (NEW) | Red | Active psoriatic arthritis after inadequate response to DMARDs |
Comments: In line with NICE TA768 |
UPADACITINIB (Rinvoq®) (NEW) | Red | Moderate rheumatoid arthritis in adults |
In line with NICE TA744 Implementation date 10th February 2022 |
VELMANASE ALFA (Lamzede ®) (NEW) | Grey | Enzyme replacement therapy for the treatment of non-neurological manifestations in patients with mild to moderate alpha mannosidosis | |
VIGABATRIN (UPDATED) | Yellow | Epilepsy |
Clarification of historical status |
Recent documents from LLR APC and TAS
Version 2 Uploaded May 2022
Date added: 31st Jul 2017
Date added: 9th May 2022
Version 1.3 Antiepileptics MHRA Feb 2019 statement uploaded April 2022
Date added: 16th May 2019
March 22 Update
Date added: 6th Aug 2020
Version 2 April 22
Date added: 20th Apr 2022
Updated version added April 2022
Date added: 2nd May 2019
Version 2 Uploaded April 22
Date added: 6th Oct 2016
Date added: 8th Apr 2022
Date added: 8th Apr 2022
Date added: 11th Mar 2022
Recall February 2022
Date added: 2nd Mar 2022
Date added: 4th Mar 2022
Uploaded April 2022
Date added: 25th Oct 2017
Date added: 2nd Mar 2022
Date added: 16th Feb 2022
Uploaded March 22
Date added: 13th Feb 2019
Uploaded March 2022
Date added: 4th Mar 2022
Uploaded March 2022
Date added: 26th May 2015
Uploaded March 22
Date added: 9th Dec 2020
Commissioned service 2022-23 Uploaded April 2022
Date added: 21st Mar 2019
Date added: 4th Feb 2022
Uploaded February 2022
Date added: 2nd Feb 2022
Version 2.0 Uploaded February 2022
Date added: 27th Jun 2018
Date added: 3rd Feb 2022
Date added: 2nd Feb 2022
Version 1.3 Uploaded January 2022
Date added: 1st Jun 2015
Date added: 14th Jan 2022
Date added: 7th Jan 2022
Date added: 4th Nov 2021
Revised Guidelines uploaded November 2021
Date added: 26th Mar 2019
Patient COPD information. Version 2 Uploaded May 2022
Date added: 7th Sep 2020
Version 2 Uploaded May 2022
Date added: 7th Sep 2020
Version 1.2 Uploaded January 2022
Date added: 16th May 2019
Version 4 uploaded May 2022
Date added: 14th Nov 2018
Shared care agreement for mesalazine for paediatric colitis.
Version 3.0 Uploaded May 2022
Date added: 9th Mar 2018
Version 2.0 Uploaded May 22
Date added: 11th May 2022
Version 4.0 including narcolepsy uploaded March 2022
Date added: 28th May 2015
Reviewed November 2021
Date added: 2nd Jul 2018
Reviewed November 2021
Date added: 2nd Jul 2018
Reviewed November 2021
Date added: 2nd Jul 2018
Reviewed November 2021
Date added: 2nd Jul 2018
Version 3 Updated November 21
Date added: 10th Dec 2021
Updated November 2021
Date added: 10th Dec 2021
Version 5.1 uploaded December 2021
Date added: 14th Nov 2017
Updated November 21
Date added: 20th Jun 2019
Wound Care Formulary Comparison Chart updated November 21
Date added: 20th Jun 2019
Updated November 2021
Date added: 10th Dec 2021
Updated November 2021
Date added: 10th Dec 2021
Form to request shared care
Version 1.2 Uploaded May 2022
Date added: 9th Mar 2018
In common with other local health communities, the Leicester, Leicestershire and Rutland Area Prescribing Committee (LLR APC) acknowledges the benefits of having a Leicestershire Health Community-wide strategy for the prescribing of specialist medicines and the managed entry of new drugs and related technologies.
Leicestershire Health Community comprises the three Clinical Commissioning Groups, University Hospitals of Leicester (UHL) NHS Trust and Leicestershire Partnership NHS Trust (LPT), amongst which there is a total consensus on the need for this strategy, and the LLR APC has been in place since 2005. Learn more